

Is primary hyperparathyroidism associated with less aggressive histological subtypes and clinicopathological features of papillary thyroid carcinoma? A large single-center cohort study

İbrahim Kılınç¹ , Mustafa Oruç¹ , Alparslan Ertenlice^{1,2} 

¹Department of General Surgery, Ankara Bilkent City Hospital, Ankara, Türkiye

²Department of General Surgery, Faculty of Medicine, Ankara Yıldırım Beyazıt University, Ankara, Türkiye

Abstract

Objective: The coexistence of primary hyperparathyroidism (PHPT) and papillary thyroid carcinoma (PTC) has been increasingly recognized; however, its impact on tumor behavior and clinicopathological features remains unclear. To investigate the association between PHPT and the clinicopathological characteristics of PTC in a large single-center cohort.

Materials and Methods: This retrospective study included patients who underwent parathyroidectomy for PHPT between 2019 and 2024. Patients with concomitant PTC were identified and compared with a separate cohort of patients with PTC without PHPT. Demographic, biochemical, and clinicopathological features, including tumor subtypes and adverse pathological characteristics, were analyzed.

Results: Among 190 patients with PTC, 91 (47.9%) had concomitant PHPT. Patients with PHPT were older and more frequently female. Tumor size was significantly smaller in patients with PHPT. Aggressive histological subtypes were significantly less frequent in the PHPT group (8.8% vs. 21.2%, $p = 0.017$). In addition, capsular invasion, lymphovascular invasion, perineural invasion, and lymph node metastasis were observed less frequently in patients with PHPT. Radioactive iodine use was also significantly lower in this group.

In the PHPT cohort ($n = 750$), the presence of concomitant PTC was not associated with significant differences in preoperative calcium, phosphorus, PTH, or ALP levels. However, patients with PTC had lower preoperative magnesium levels and exhibited distinct postoperative biochemical profiles.

Conclusion: PHPT may be associated with non-aggressive subtypes and more favorable clinico-pathological features in PTC. However, these findings should be interpreted cautiously, as tumor size and other potential confounders may influence the observed associations. PHPT alone should not be considered a determinant for treatment de-escalation, and clinical decision-making should remain guided by established risk-adapted strategies. These findings may provide additional insight into risk stratification in patients with coexisting PHPT and PTC.

Keywords: hyperparathyroidism, thyroid cancer, papillary

Corresponding author: İbrahim Kılınç • Email: ikilinc8083@gmail.com

Received: April 13, 2026 Accepted: April 28, 2026 Published online: June 28, 2026

Copyright © 2026 The Author(s). Published by Hacettepe University Faculty of Medicine. This is an open access article distributed under the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

Introduction

Primary hyperparathyroidism (PHPT) is a common endocrine disorder affecting approximately 0.1–0.4% of the general population [1]. In the majority of cases, it is caused by a solitary parathyroid adenoma, and surgical excision remains the definitive treatment [2]. Given the relatively high prevalence of concomitant thyroid pathology, preoperative thyroid evaluation is routinely recommended in patients undergoing parathyroidectomy [3].

Papillary thyroid carcinoma (PTC), accounting for 85–90% of all thyroid malignancies, is the most common type of thyroid cancer, with a steadily increasing incidence worldwide over recent decades [4,5]. Although several studies have reported an association between PHPT and thyroid carcinoma [6,7], the nature of this relationship remains incompletely understood [8]. In particular, it is still unclear whether this coexistence reflects a causal link or represents a coincidental finding, and further investigation is required to clarify the underlying mechanisms.

Potential shared molecular pathways and genetic predispositions contributing to the coexistence of these two conditions have been proposed, but current evidence remains limited [9,10]. Moreover, comprehensive studies evaluating the impact of PHPT on the prognosis, disease progression, and treatment outcomes of PTC—as well as the potential influence of PTC on the clinical course of PHPT—are scarce [11,12].

A better understanding of the clinical implications of this coexistence is of considerable importance, particularly in terms of diagnostic challenges, surgical planning, and treatment strategies [7,12–14].

Therefore, the aim of this study was to systematically evaluate the potential interaction between PHPT and PTC in a large patient cohort.

Materials and Methods

Study design and patient selection

This retrospective study was conducted in two phases. In the first phase, all consecutive patients with PHPT who underwent surgery at our institution between January 2019 and December 2024 were included.

All procedures were performed by attending surgeons from the Department of General Surgery.

During this period, a total of 816 patients underwent parathyroidectomy. Of these, 67 patients were excluded due to secondary or tertiary hyperparathyroidism ($n = 36$), familial syndromes such as MEN1 or MEN2A ($n = 7$), incomplete medical records ($n = 17$), or unsuccessful parathyroidectomy ($n = 6$). After applying these exclusion criteria, 750 patients were included in the final analysis and were stratified according to the presence or absence of concomitant PTC (Figure 1).

In the second phase, to enable comparison between patients with PTC with and without PHPT, a separate cohort of patients with PTC without PHPT was included. These patients were selected from consecutive cases who underwent surgery between January 2019 and December 2020 and had a histopathological diagnosis of PTC, in order to achieve a comparable sample size with the PTC + PHPT group. This approach was chosen to minimize temporal bias and ensure a homogeneous surgical and diagnostic environment following the establishment of our high-volume center in 2019.

Patients with concomitant PHPT and PTC were included in both analytic cohorts, as each analysis addressed a distinct research question.

Data collection

Preoperative and postoperative biochemical data were retrieved from institutional electronic medical records. All biochemical analyses were performed in the central laboratory of our institution using




Figure 1. Flowchart of the study population and patient selection process

standardized automated analyzers in accordance with the manufacturers' instructions.

Alkaline phosphatase (ALP), calcium, phosphorus, magnesium, and creatinine levels were measured using the Siemens Atellica CH automated chemistry analyzer (Siemens Healthineers, Erlangen, Germany), employing IFCC-recommended kinetic colorimetric or enzymatic methods, as appropriate. Parathyroid hormone (PTH) levels were measured using chemiluminescent immunoassay on the Siemens Atellica IM analyzer.

The reference ranges were as follows: ALP 42–98 U/L, calcium 8.7–10.4 mg/dL, phosphorus 2.4–5.1 mg/dL, magnesium 1.3–2.7 mg/dL, and creatinine 0.5–1.1 mg/dL. The reference range for serum PTH was 18.4–80.1 ng/mL.

Serum calcium concentrations were corrected for albumin using the following formula:

Corrected calcium (mg/dL) = $[0.08 \times (40 - \text{albumin (g/L)})] + \text{measured calcium}$.

Laboratory parameters were collected at predefined perioperative time points. Magnesium and phosphorus levels obtained during the final week prior to surgery were recorded. PTH levels included the highest preoperative value measured within one month before surgery and the postoperative value measured on postoperative day 1. Similarly, calcium levels were defined as the highest preoperative value within one month prior to surgery and the postoperative value measured on postoperative day 1.

Clinical and pathological data

Data on PTC were obtained from pathology reports. Parathyroid adenoma localization and dimensions were determined based on preoperative ultrasonography and operative records. Adenomas were assumed to have an ellipsoid shape, and their volumes were calculated using the formula: $\text{volume} = (\pi/6) \times \text{length} \times \text{width} \times \text{depth}$.

Patients with renal stones detected on imaging (ultrasonography or computed tomography) or with a documented history of nephrolithiasis were classified as having a history of renal stones.

Definitions

PHPT with PTC was defined as the coexistence of histopathologically confirmed para-thyroid tumor and PTC in the same patient, with both lesions identified and treated during the same surgical procedure.

PTC subtypes were classified according to the World Health Organization criteria.

Aggressive PTC subtypes were defined as tall cell, hobnail, columnar cell, diffuse sclerosing, and solid/trabecular variants, based on their established association with adverse clinicopathological features. Other subtypes—including classic (conventional), follicular, Warthin-like, oncocytic, and cribriform-molar variants—were not classified as aggressive.

Bone health was assessed using bone mineral density (BMD) and T-scores obtained from dual-energy X-ray absorptiometry (DXA) of the lumbar spine. Lumbar spine measurements were selected because they represented the most consistently available data in this retrospective cohort (missing in only 8 patients). Measurements from the radius, femoral neck, and total hip were not consistently available and were therefore excluded from analysis.

DXA measurements were performed using a GE/Lunar Prodigy densitometer (GE Healthcare, Madison, WI, USA) according to standard protocols. The precision error for lumbar spine BMD measurements was within acceptable limits, with a coefficient of variation (CV) $\leq 2\%$, in accordance with international densitometry standards.

Statistical analysis

Continuous variables were assessed for normality using visual inspection and the Shapiro–Wilk test and are presented as mean $\pm$ standard deviation (SD) or median with interquartile range (IQR), as appropriate. Categorical variables are expressed as frequencies and percentages.

Comparisons between groups were performed using Student's t-test or the Mann–Whitney U test for continuous variables and the chi-square test or Fisher's exact test for categorical variables, as appropriate.

A two-sided p -value < 0.05 was considered statistically significant. All statistical analyses were performed using R software (version 4.1.1).

Ethical approval

This study was conducted in accordance with the ethical principles of the Declaration of Helsinki. The study protocol was approved by the local Ethics Committee (approval number: TABED 1-25-1568). Informed consent was obtained from all participants as part of the routine institutional admission procedure, which includes permission for the retrospective use of anonymized clinical data for scientific research purposes.

Results

Comparison of PTC with and without concomitant PHPT

Among 190 patients with PTC, 91 (47.9%) had concomitant PHPT. Patients with PTC and PHPT were older than those without PHPT (55 ± 11 vs. 47 ± 14 years,

$p < 0.001$) and were more frequently female (89% vs. 71.7%, $p = 0.003$). The distribution of conventional (classic) PTC was similar in patients with and without PHPT (78.1% vs. 78.7%). In contrast, the follicular subtype was more common in patients without PHPT (42.4% vs. 33.0%) (Figure 2). Aggressive PTC subtypes were more frequently observed in patients without PHPT (21.2% vs. 8.8%, $p = 0.017$).

Patients without PHPT demonstrated higher rates of adverse pathologic features, including capsule invasion (31.3% vs. 17.6%, $p = 0.028$), lymphovascular invasion (20.2% vs. 6.6%, $p = 0.006$), perineural invasion (11.1% vs. 3.3%, $p = 0.039$), and central lymph node metastasis (29.3% vs. 6.6%, $p < 0.001$). Lateral lymph node metastasis was observed exclusively in patients without parathyroid adenoma (PA) (7.9% vs. 0%, $p < 0.001$). Radioactive iodine therapy was administered more frequently to patients without PHPT (80.8% vs. 21.1%, $p < 0.001$). The rates of multifocality, bilaterality, recurrence, and follow-up duration did not differ significantly between the groups (Table 1).




Figure 2. Distribution of PTC subtypes in patients with or without concomitant PHPT

Percentage distribution of papillary thyroid carcinoma subtypes in patients with and without parathyroid adenomas. PHPT: Primary Hyperparathyroidism; PTC: papillary thyroid carcinoma. Percentages may exceed 100% due to the presence of mixed histological patterns.

Table 1. Comparison of PTC with or without PHPT

Variables	Total (n=190)	PTC without PHPT (n=99)	PTC with PHPT (n=91)	p
Age, years, mean, SD	51 ± 14	47 ± 14	55 ± 11	<0.001
Sex, female, n, %	152 (80)	71 (71.7)	81 (89)	0.003
Tumor Size, cm, median, IQR	12 (6-17)	15 (12-25)	6 (3-9)	<0.001
Aggressive tumor variant, n, %	29 (15.3)	21 (21.2)	8 (8.8)	0.017
Multifocal tumor, n, %	86 (45.3)	47 (47.5)	38 (42.9)	0.523
Bilateral tumor, n, %	61 (32.1)	35 (35.4)	26 (28.6)	0.317
Capsule Invasion, n, %	47 (24.7)	31 (31.3)	16 (17.6)	0.028
Extrathyroidal extension, n, %	41 (21.7)	27 (27.3)	14 (15.6)	0.051
Lymphovascular Invasion, n, %	26 (13.7)	20 (20.2)	6 (6.6)	0.006
Perineural Invasion, n, %	14 (7.4)	11 (11.1)	3 (3.3)	0.039
Central Lymph Node Metastasis, n, %	35 (18.4)	29 (29.3)	6 (6.6)	<0.001
Lateral Lymph Node Metastasis, n, %	15 (7.9)	15 (15.1)	0 (0)	<0.001
Radioactive Iodine Treatment, n, %	99 (52.4)	80 (80.8)	19 (21.1)	<0.001
Recurrence, n, %	3 (1.6)	3 (3)	0 (0)	0.247
Follow up time, months, median, IQR	18 (10-35)	16 (7-33)	20 (11-35)	0.09

IQR: Interquartile range, PHPT: Primary Hyperparathyroidism, PTC: Thyroid Papillary Carcinoma, SD: Standard Deviation.

Comparison of PHPT with and without concomitant PTC

A total of 750 patients with parathyroid pathology were included, of whom 91 (12.1%) had concomitant PTC. Patients with PHPT and concomitant PTC were slightly older than those without PTC (55 ± 11 vs. 52 ± 12 years, $p = 0.002$) and were more frequently female (89% vs. 80%, $p = 0.03$).

The preoperative biochemical parameters, including serum calcium, phosphorus, parathyroid hormone (PTH) and ALP levels, were largely comparable between the groups. However, patients with concomitant PTC had significantly lower preoperative magnesium levels (median 1.99 vs. 2.07 mg/dL, $p = 0.003$).

Postoperatively, patients with PA and PTC had significantly lower calcium levels (median 8.48 vs. 8.90 mg/dL, $p < 0.001$), higher phosphorus levels (3.50 ± 0.81 vs. 3.21 ± 0.64 mg/dL, $p = 0.001$), and lower PTH levels (median 10 vs. 17 pg/mL, $p = 0.002$). Parathyroid gland location, pathology subtype, size, and volume did not differ significantly between the groups. Similarly, the prevalence of renal stones, bone mineral density,

and T-scores were comparable between patients with and without concomitant PTC (Table 2).

Discussion

In this large cohort study, we compared patients with PTC with and without concomitant PHPT in terms of demographic, biochemical, and clinicopathological characteristics. Our findings suggest that the presence of PHPT may be associated with differences in tumor behavior and could represent a clinically relevant factor in the evaluation of PTC. In addition, we performed a secondary analysis comparing patients with isolated PHPT and those with concomitant PTC across similar parameters.

Previous studies investigating the coexistence of PHPT and PTC have predominantly focused on the prevalence of thyroid disease in patients with PHPT, frequently reporting a high incidence of papillary thyroid microcarcinomas (PTMCs) and incidentally detected tumors in this population [14-17]. However, to the best of our knowledge, large-scale studies systematically comparing the distribution of aggressive histological

Table 2. Comparison of PHPT with or without PTC

Variables	Total (n=750)	PHPT without PTC (n=659)	PHPT with PTC (n=91)	p
Age, years, mean, SD	53 ± 12	52 ± 12	55 ± 11	0.002
Sex, female, n, %	608 (81.1)	527 (80)	81 (89)	0.03
Preoperative Laboratory Values				
ALP, U/L, median, IQR	108 (85-137)	107 (84-136)	109 (88-149)	0.313
Calcium, mg/dL, median, IQR	11.52 (11.08-11.96)	11.53 (11.09-11.97)	11.41 (11.03-11.92)	0.483
Phosphorus, mg/dL, mean, SD	2.62 ± 0.56	2.61 ± 0.55	2.69 ± 0.62	0.109
Magnesium, mg/dL, median IQR	2.06 (1.91-2.19)	2.07 (1.92-2.2)	1.99 (1.83-2.13)	0.003
Creatinine, mg/dL, median, IQR	0.74 (0.64-0.86)	0.73 (0.64-0.85)	0.76 (0.64-0.87)	0.483
PTH, pg/mL, median, IQR	192 (139-273)	191 (139-271)	205 (137-311)	0.650
Postoperative Laboratory Findings				
Calcium, mg/dL, median, IQR	8.85 (8.44-9.32)	8.90 (8.49-9.37)	8.48 (7.91-8.89)	<0.001
Phosphorus, mg/dL, mean, SD	3.25 ± 0.67	3.21 ± 0.64	3.50 ± 0.81	0.001
PTH, pg/mL, median, IQR	16 (9-35)	17 (9-36)	10 (4.5-29.7)	0.002
Parathyroid location, n, %				0.119
Left Superior	88 (11.7)	81 (12.3)	7 (7.7)	
Left Inferior	273 (36.4)	240 (36.4)	33 (36.3)	
Right Superior	89 (11.9)	82 (12.4)	7 (7.7)	
Right Inferior	248 (33.1)	212 (32.2)	36 (39.6)	
Intrathyroidal	34 (4.5)	31 (4.7)	3 (3.3)	
Atypic	18 (2.4)	13 (2)	5 (5.5)	
Parathyroid pathology n, %				0.567
Adenoma	687 (91.8)	605 (91.9)	82 (90.1)	
Atypic adenoma	25 (3.3)	22 (3.3)	3 (3.3)	
Hyperplasia	32 (4.3)	26 (4)	6 (6.6)	
Cancer	5 (0.7)	5 (0.7)	0 (0)	
Parathyroid size, mm, median, IQR	12 (9-17)	12 (9-16)	12 (9-18)	0.343
Parathyroid volume mm ³ , median, IQR	374.6 (164.8-918.3)	363 (164.4-863.9)	457 (164-1706)	0.121
History of Renal Stone, n, %	169 (23)	153 (23.8)	16 (17.6)	0.188
BMD g/cm ³ , median, IQR	0.99 (0.88-1.10)	0.99 (0.88-1.10)	0.96 (0.82-1.13)	0.170
T Score, median, IQR	-1.40 (-2.40 - -0.5)	-1.40 (-2.40 - -0.50)	-1.70 (-2.70 - -0.4)	0.160

ALP: Alkaline Phosphatase, BMD: Bone Mass Density, IQR: Interquartile range, PHPT: Primary Hyperparathyroidism, PTH: Parathyroid Hormone, PTC: Thyroid Papillary Carcinoma, SD: Standard Deviation.

subtypes and other adverse clinicopathological features between PTC patients with and without PHPT remain limited. In the present study, we evaluated not only tumor frequency but also a wide range of prognostic parameters reflecting tumor biology and clinical

behavior. Our findings suggest that PTC associated with PHPT may exhibit a more indolent clinicopathological phenotype compared with isolated PTC. Nevertheless, a causal relationship cannot be established based on the current data.

The existing literature on this topic is heterogeneous. Beebejaun et al. proposed that elevated PTH levels, hypercalcemia, and low 1,25-dihydroxyvitamin D levels may influence the tumor microenvironment and thereby alter the biological behavior of PTC [8]. Similarly, Jeong et al. and Çetin et al. reported that PTC associated with PHPT may present with more aggressive histopathological and clinical features [6,7]. In contrast, Hu et al. found no significant difference in tumor aggressiveness between PTC patients with and without PHPT, while Tsai et al. suggested that PTC associated with PHPT may follow an indolent course, potentially due to earlier detection [18]. These conflicting findings highlight the need for further well-designed studies to clarify the nature of this association.

One of the most notable findings of our study is the significantly lower frequency of aggressive histological subtypes—such as tall cell and hobnail variants, which are well known to be associated with poor prognosis and higher invasive potential—in patients with concomitant PHPT [19]. In addition, rates of capsular invasion, lymphovascular invasion, and perineural invasion were significantly lower in this group, while extrathyroidal extension showed a trend toward lower frequency. The lower rate of lymph node metastasis further supports the notion that these tumors may exhibit a more indolent biological behavior [20-22].

However, the significantly smaller tumor size observed in patients with concomitant PHPT should be considered an important confounding factor that may partially account for the lower rates of invasion and metastasis. Therefore, it would be inappropriate to attribute the less aggressive clinicopathological features solely to the presence of PHPT without accounting for tumor size differences. In this context, tumor size should be taken into consideration when interpreting the observed differences between groups. Adjuvant treatment patterns may also reflect these differences in tumor characteristics. The lower rate of radioactive iodine (RAI) use in patients with concomitant PHPT may suggest that these tumors are more frequently classified into lower-risk categories. Given that current guidelines recommend a more selective use of RAI in low-risk PTC patients [23,24], this finding may indicate that unnecessary adjuvant treatments could potentially be avoided in this sub-group. However, the difference in RAI use should be interpreted cautiously, as it likely reflects risk-adapted clinical decision-making rather than intrinsic tumor biology.

It has been suggested that PTC associated with PHPT may be detected at smaller sizes due to increased diagnostic scrutiny, leading to a more indolent clinical course [25]. This raises the possibility that detection bias may contribute to the observed differences in tumor behavior. However, the lower frequency of aggressive histological variants observed in our study suggests that the indolent phenotype can-not be explained solely by earlier detection and may also reflect underlying biological differences.

From a biological perspective, the chronic hypercalcemic microenvironment characteristic of PHPT may modulate calcium-sensing receptor (CaSR)-mediated signaling pathways, thereby influencing cellular proliferation and differentiation processes [26,27]. In addition, the observed indolent phenotype may speculatively reflect differences in the underlying molecular landscape, including a lower prevalence of alterations associated with aggressive behavior, such as BRAFV600E and TERT promoter mutations [28]. However, these hypotheses require validation in future molecular and prospective studies.

The lower frequency of aggressive histological variants in PTC associated with PHPT may also be considered in the context of the risk-adapted approach emphasized in the American Thyroid Association (ATA) 2025 guidelines. Current recommendations define recurrence risk based on a combination of pathological features, with the accumulation of adverse characteristics leading to higher risk categories [24]. In this regard, the lower rates of aggressive subtypes, lymph node metastasis, and other invasive features observed in patients with PHPT suggest that these tumors may be more likely to fall into lower-risk categories. However, given the differences in tumor size between groups and the absence of multivariable analyses, caution is warranted when translating these findings into clinical decision-making.

In our secondary analysis comparing patients with PHPT with and without concomitant PTC, preoperative biochemical parameters were largely similar between groups. The absence of significant differences in serum calcium, phosphorus, PTH, and ALP levels suggests that the presence of PTC is not associated with the biochemical severity of PHPT. This finding supports the notion that the two conditions may largely follow independent biochemical courses. Interestingly, preoperative magnesium levels were significantly lower in patients with concomitant PTC. Given the

potential role of magnesium in cellular proliferation and oxidative stress, this finding may indicate a possible interaction between mineral metabolism and thyroid tumor biology. Our results are consistent with previous studies reporting an association between low serum magnesium levels and thyroid cancer [29,30]. Postoperatively, patients with concomitant PTC exhibited lower calcium and PTH levels and higher phosphorus levels, suggesting a different balance of mineral metabolism following surgery. However, the absence of differences in parathyroid gland size, volume, localization, and pathological characteristics suggests that these findings may be more closely related to surgical extent or perioperative factors rather than intrinsic disease burden. Furthermore, the similar rates of renal stone history, bone mineral density, and T-scores between groups indicate that end-organ involvement in PHPT appears to be independent of the presence of concomitant PTC. Taken together, these findings suggest that the coexistence of PTC does not substantially alter the systemic clinical manifestations of PHPT.

Several limitations of this study should be acknowledged. First, the retrospective design and baseline differences between groups—particularly in age, sex, and tumor size—limit the ability to fully account for potential confounding factors. Second, the absence of multivariable analyses precludes definitive assessment of the independent effect of PHPT. Finally, the relatively short follow-up period restricts the evaluation of recurrence and long-term oncological outcomes.

In conclusion, this study suggests that PHPT may be associated with non-aggressive subtypes of PTC and that these tumors may exhibit less aggressive clinicopathological features compared with isolated PTC. The lower frequency of aggressive histological variants, invasive features, and lymph node metastasis supports the notion of a more indolent tumor phenotype. While the more favorable pathological profile observed in patients with concomitant PHPT appears to be consistent with the risk-adapted approach emphasized in the ATA 2025 guidelines, PHPT itself should not be considered an independent criterion for treatment de-escalation. Clinical decision-making in this patient population should remain guided by established guidelines and multidisciplinary evaluation. These findings may provide additional insight into risk stratification in patients with coexisting PHPT and PTC.

Author contributions

Conception: İ.K., M.O., A.E.; Design: İ.K.; Data acquisition: İ.K., A.E.; Data analysis: M.O.; Data interpretation: İ.K., M.O., A.E.; Drafting of the manuscript: İ.K., A.E.; Critical revision of the manuscript: İ.K., M.O., A.E. All authors reviewed the results, approved the final version of the manuscript, and agreed to be accountable for all aspects of this study.

Ethical approval

This study was approved by the Ankara Bilkent City Hospital-Medical Research and Clinical Ethics Evaluation Committee (Date: 13.08.2025, Decision/Protocol No: TABED 1-25-1568). Informed consent was obtained from all participants involved in this study.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflict of interest

The authors declare that this study was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding

The authors declare that this study received no funding.

Generative AI statement

The authors declare that no generative AI or AI-assisted technologies were used in the writing or preparation of this study.

References

- [1] Heath DA. Primary hyperparathyroidism. Clinical presentation and factors influencing clinical management. *Endocrinol Metab Clin North Am* 1989;18(3):631-46.
- [2] Fraser WD. Hyperparathyroidism. *Lancet* 2009;374(9684):145-58. [\[Crossref\]](#)
- [3] Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons Guidelines for definitive management of primary hyperparathyroidism. *JAMA Surg* 2016;151(10):959-68. [\[Crossref\]](#)
- [4] Noone AM, Howlander N, Krapcho M, et al. SEER cancer statistics review, 1975-2015. National Cancer Institute 2018. Available at: https://seer.cancer.gov/csr/1975_2015/.
- [5] Vaccarella S, Dal Maso L, Laversanne M, Bray F, Plummer M, Franceschi S. The impact of diagnostic changes on the rise in thyroid cancer incidence: a population-based study in selected high-resource countries. *Thyroid* 2015;25(10):1127-36. [\[Crossref\]](#)
- [6] Çetin K, Sıkar HE, Temizkan Ş, et al. Does primary hyperparathyroidism have an association with thyroid papillary cancer? A retrospective cohort study. *World J Surg* 2019;43(5):1243-8. [\[Crossref\]](#)
- [7] Jeong C, Kwon HI, Baek H, et al. Association of hyperparathyroidism and papillary thyroid cancer: a multicenter retrospective study. *Endocrinol Metab (Seoul)* 2020;35(4):925-32. [\[Crossref\]](#)
- [8] Beebeejaun M, Chinnasamy E, Wilson P, Sharma A, Beharry N, Bano G. Papillary carcinoma of the thyroid in patients with primary hyperparathyroidism: is there a link? *Med Hypotheses* 2017;103:100-4. [\[Crossref\]](#)
- [9] Vargas-Ortega G, Balcázar-Hernández L, González-Virla B, et al. Symptomatic primary hyperparathyroidism as a risk factor for differentiated thyroid cancer. *J Thyroid Res* 2018;2018:9461079. [\[Crossref\]](#)
- [10] Emami A, Nazem MR, Shekarri R, Hedayati M. Micronutrient status (calcium, zinc, vitamins D and E) in patients with medullary thyroid carcinoma: a cross-sectional study. *Nutrition* 2017;41:86-89. [\[Crossref\]](#)
- [11] Nilsson IL, Zedenius J, Yin L, Ekblom A. The association between primary hyperparathyroidism and malignancy: nationwide cohort analysis on cancer incidence after parathyroidectomy. *Endocr Relat Cancer* 2007;14(1):135-40. [\[Crossref\]](#)
- [12] Palmieri S, Roggero L, Cairoli E, et al. Occurrence of malignant neoplasia in patients with primary hyperparathyroidism. *Eur J Intern Med* 2017;43:77-82. [\[Crossref\]](#)
- [13] Chinamon U, Levy D, Marom T. Is primary hyperparathyroidism a risk factor for papillary thyroid cancer? An exemplar study and literature review. *Int Arch Otorhinolaryngol* 2015;19: 42-5.
- [14] Kutlutürk K, Otan E, Yağcı MA, Usta S, Aydın C, Ünal B. Thyroid pathologies accompanying primary hyperparathyroidism: a high rate of papillary thyroid microcarcinoma. *Ulus Cerrahi Derg* 2014;30(3):125-8. [\[Crossref\]](#)
- [15] Li L, Li B, Lv B, et al. Increased thyroid malignancy in patients with primary hyperparathyroidism. *Endocr Connect* 2021;10(8):885-93. [\[Crossref\]](#)
- [16] Xue Y, Ye ZQ, Zhou HW, Shi BM, Yi XH, Zhang KQ. Serum calcium and risk of nonmedullary thyroid cancer in patients with primary hyperparathyroidism. *Med Sci Monit* 2016;22:4482-9. [\[Crossref\]](#)
- [17] Preda C, Branisteanu D, Armasu I, et al. Coexistent papillary thyroid carcinoma diagnosed in surgically treated patients for primary versus secondary hyperparathyroidism: same incidence, different characteristics. *BMC Surg* 2019;19(1):94. [\[Crossref\]](#)
- [18] Tsai CY, Chen ST, Hsueh C, Lin YS, Lin JD. Long-term therapeutic outcomes of papillary thyroid carcinoma with concomitant hyperparathyroidism: a single center case-control study. *Biomed J* 2020;43(1):53-61. [\[Crossref\]](#)
- [19] Baloch ZW, Asa SL, Barletta JA, et al. Overview of the 2022 WHO classification of thyroid neoplasms. *Endocr Pathol* 2022;33(1):27-63. [\[Crossref\]](#)
- [20] Jeon MJ, Chung MS, Kwon H, et al. Features of papillary thyroid microcarcinoma associated with lateral cervical lymph node metastasis. *Clin Endocrinol (Oxf)* 2017;86(6):845-51. [\[Crossref\]](#)
- [21] Jeon MJ, Kim WG, Choi YM, et al. Features predictive of distant metastasis in papillary thyroid microcarcinomas. *Thyroid* 2016;26(1):161-8. [\[Crossref\]](#)
- [22] Kim SK, Park I, Woo JW, et al. Predictive factors for lymph node metastasis in papillary thyroid microcarcinoma. *Ann Surg Oncol* 2016;23(9):2866-73. [\[Crossref\]](#)
- [23] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. *Thyroid* 2016;26(1):1-133. [\[Crossref\]](#)
- [24] Ringel MD, Sosa JA, Baloch Z, et al. 2025 American Thyroid Association Management Guidelines for adult patients with differentiated thyroid cancer. *Thyroid* 2025;35(8):841-985. [\[Crossref\]](#)
- [25] Liu Y, Guo S, Sang S, et al. Differences in clinicopathological characteristics of papillary thyroid carcinoma between symptomatic and asymptomatic patients with primary hyperparathyroidism. *Int J Endocrinol* 2021;2021:9917694. [\[Crossref\]](#)
- [26] Saidak Z, Mentaverri R, Brown EM. The role of the calcium-sensing receptor in the development and progression of cancer. *Endocr Rev* 2009;30(2):178-95. [\[Crossref\]](#)

- [27] Tennakoon S, Aggarwal A, Kállay E. The calcium-sensing receptor and the hallmarks of cancer. *Biochim Biophys Acta* 2016;1863(6 Pt B):1398-407. [\[Crossref\]](#)
- [28] Liu C, Chen T, Liu Z. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis. *World J Surg Oncol* 2016;14(1):241. [\[Crossref\]](#)
- [29] Shen F, Cai WS, Li JL, Feng Z, Cao J, Xu B. The association between serum levels of selenium, copper, and magnesium with thyroid cancer: a meta-analysis. *Biol Trace Elem Res* 2015;167(2):225-35. [\[Crossref\]](#)
- [30] Xu H, Hu X, Li J, et al. The Inverse Association of serum magnesium with papillary thyroid cancer in thyroid nodules: a cross-sectional survey based on thyroidectomy population. *Biol Trace Elem Res* 2023;201(7):3279-89. [\[Crossref\]](#)